Back to top
more

Alcon (ALC)

(Delayed Data from NYSE)

$89.28 USD

89.28
1,955,924

+8.36 (10.33%)

Updated May 14, 2024 04:00 PM ET

After-Market: $89.27 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings

by Zacks Equity Research

Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.

What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) second-quarter results are likely to benefit from better patient volumes. The results might partly suffer from escalating labor costs that might dampen bottom line growth.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Strong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.

Alcon's (ALC) Product Launches, Market Recovery Aid Growth

by Zacks Equity Research

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

What's in Store for Thermo Fisher (TMO) in Q2 Earnings?

by Zacks Equity Research

The emergence of the new virus variants, through the months of Q2, is likely to have led to top-line contributions within Thermo Fisher's (TMO) Life-Science Solutions segment.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.

What's in Store for Boston Scientific (BSX) in Q2 Earnings?

by Zacks Equity Research

Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

by Zacks Equity Research

Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q2 on the continuous rollout of Alinity.

Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?

by Zacks Equity Research

Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.

Here's Why Alcon (ALC) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Investors Should Retain Alcon (ALC) Stock For Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals

by Zacks Equity Research

The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.

Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow

by Zacks Equity Research

Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.

Trina Mukherjee headshot

3 Medical Product Stocks Set to Beat on Earnings This Season

by Trina Mukherjee

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

What's in the Offing for Synaptics (SYNA) This Earnings Season?

by Zacks Equity Research

Synaptics' (SYNA) third-quarter fiscal 2022 performance is likely to have benefited from increased bookings and new Organic Light Emitting Diode touch-sensor design wins.

EPAM Systems (EPAM) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Though the accelerated digital modernization across industries is likely to aid EPAM Systems' (EPAM) Q1 results, the discontinuation of Russian operations is likely to have hurt the top and bottom lines.

Ball Corp (BLL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Ball Corp's (BLL) Q1 performance is likely to reflect benefits from solid demand for beverage can packaging, can plant capacity expansions and robust aerospace backlog.

fuboTV (FUBO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

fuboTV's (FUBO) first-quarter results are expected to reflect growth in paid subscribers and viewing supported by increased advertiser demand on the company's sports-first live TV streaming platform.

Block (SQ) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Block's (SQ) first-quarter results are expected to reflect strength across its seller base and omnichannel offerings amid rising expenses and the pandemic-led uncertainties.

eBay (EBAY) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

eBay's (EBAY) first-quarter 2022 results are likely to reflect the impacts of strong momentum across Promoted Listings and Managed payments.

Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums

by Zacks Equity Research

Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.

Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services

by Zacks Equity Research

Humana (HUM) still has $2 billion remaining under its share repurchase authorization.

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up

by Zacks Equity Research

Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.